Towards engineering approaches that are designed to optimize the particle size, morphology and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on "spray-drying engineered" α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl-alcohol), aerosolization (L-leucine) and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution and in vitro mucoadhesion profiles is presented along with "Calu-3 cell monolayers" data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide.
INTRODUCTION
Elevated blood flow and a large surface area (100 m 2 ) render the human lung network a suitable site for the rapid absorption of therapeutic compounds. 1 The pulmonary delivery of drugs by means of inhaled aerosols is regarded as a minimally invasive route of administration and offers the additional advantages that are associated with the avoidance of the hepatic first-pass effect.
The benefits of the approach are counterbalanced by the challenges associated with the efficient delivery of therapeutic formulations to the lungs, which is often impeded by physiological barriers that inhibit the efficient deposition, residence time and drug release characteristics of formulations. For effective delivery of therapeutic compounds to the alveolar area of the lungs, it is desirable that solid components of inhalable formulations have a mean aerodynamic diameter in the range 1-5 µm. 2 Associated with this are the good aerosolization properties of particles, such that aggregation is prevented. 3 Also, to overcome the action of the mucociliary apparatus, 4, 5 the particles must be mucoadhesive, such as to become instantaneously integrated into the mucosa layer of the lungs. To this end, many excipients (sugars, 6, 7 lipids, 8, 9 amino acids, 10,11 polymers 12, 13 ) have been evaluated 14 but lactose has remained the material of choice for commercial formulations over many years. 15 The method of choice for the manufacturing of both local and systemic formulations for the delivery of therapeutic agents to the respiratory system is spray drying.
3, 16, 17 Within the context of particle engineering, spray drying is an established method for the formulation of drug-loaded particles since it is compatible a wide range of materials 18 and offers the capability to fine-tune multicomponent formulations through the incorporation of an array of well-studied excipients in a one-step method that allows the ready incorporation of therapeutic compounds. [19] [20] [21] [22] 4 This paper describes the engineering, by spray drying, of multicomponent formulations for the pulmonary delivery of the corticosteroid budesonide (BD), which is widely used for the treatment of asthma. In accord with established technologies, the bulk material of the formulation is α-lactose monohydrate (LCS). The other components of the formulation include: polyvinyl alcohol (PVA), which is reported to enhance the morphological characteristics of particles and to improve their drug-release properties; [23] [24] [25] dipalmitoylphosphatidylcholine (DPPC) lung surfactant; [26] [27] [28] [29] L-leucine (L-LC) aerolization modifier; 25, 30, 31 and chitosan (CS) bioadhesive. [32] [33] [34] [35] To facilitate the selection of optimal compositions, these formulations are assessed for their production yield, morphological characteristics, and surface charge. Thermal analysis and infrared spectroscopy are used to further characterize promising formulations, and these studies are complemented by laser diffraction investigations of particle size distribution and aerolization performance, and also by in vitro deposition studies. The in vitro release of the incorporated active is assessed in simulated lung fluid. To simulate the in vivo challenges that are presented to the formulations by the mucosal barrier at the surfaces of the lung, assessment tools are deployed for the evaluation of the mucoadhesive properties of the microparticles under investigation. Both the adhesion profiles of microparticles in contact with mucus and the effects of this interaction on the cohesiveness of the resultant gel are considered for the purpose of identifying a potentially therapeutically useful formulation. Finally, cell proliferation and epithelial integrity studies are used to evaluate the effect of formulations on the Calu-3 cell line.
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EXPERIMENTAL SECTION
Materials. Budesonide (≥99%), polyvinyl alcohol (Mowiol 4-88, MW~31000), L-leucine (≥98%), low molecular weight chitosan (MW 50000-190000), Rhodamine B (≥95%), diethylenetriaminepentaacetic acid (≥99%), RPMI 1640 amino acids solution, deoxyribonucleic acid sodium salt from salmon testes, mucin from porcine stomach type II and gelatin from bovine skin type B were all purchased from Sigma-Aldrich, Germany. α-Lactose monohydrate was purchased from DMV International, Netherlands. Egg Yolk Emulsion for Microbiology was sourced from Merck, Germany. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) was obtained from Avanti Polar Lipids. All other materials and reagents were of analytical grade.
Homogenised
Mucus. An aqueous mixture was prepared from sodium chloride (0.9% w/v), the bacteriostatic agent sodium azide (0.02% w/v), the oxidation-inhibiting chelating agent ethylenediaminetetraacetic acid (0.186% w/v) and an ethanolic solution (1ml) of the protease (cell-degradation) inhibitor phenylmethylsulphonyl fluoride (0.0175% w/v). The mixture was made up to 100ml with distilled water and brought into the solution phase by stirring (12 hours, room temperature). In accord with the procedures dictated by the Science Faculty Ethics Committee of the University of Portsmouth, crude sputum (100 ml) was collected from two unfed (3 hours) healthy human volunteers (one male, one female; both 24 years of age) over a period of approximately 3 hours (The average daily flow of whole saliva in healthy subjects varies between 1 and 1.5 L
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) and subjected to vacuum (Buchner) filtration (twice) to remove any buccal cells, food debris and other large particles. The thus treated mucus was preserved by freezing at -18ºC.
Preparation of engineered microparticles. Three sets of multicomponent carriers (MCs) were produced by the spray drying technique, namely: budesonide-free (empty), budesonide-loaded 6 and Rhodamine B-loaded microparticles. For each set, the effect of variations in the proportions of excipients was assessed at two specified ratios of the utilized liquid media (water and ethanol).
The compositions of empty formulations are listed at Table 1. The excipients PVA, LCS, DPPC, CS and L-LC were incorporated into the formulation from feed solutions. To prepare each formulation, the lipid DPPC was dissolved in a specified volume (70 or 85 mL) of ethanol. In parallel, PVA was dissolved in a predetermined amount of hot (90 ºC) water (either 25 or 10mL), and once PVA had dissolved, LCS and L-LC were added in sequence to each solution.
Separately, CS was dissolved in water containing 1% acetic acid (5 mL). The two aqueous solutions were mixed to form the aqueous phase, which in turn was added very slowly to the organic phase -such as to avoid the precipitation of the lipid compound or the formation of liposomal structures. The mixing of the alcoholic and aqueous solution was in such ratios as to afford formulations that had a total volume of 100 mL and a solid content of 0.1% w/v.
To prepare loaded formulations, selected compositions of empty feed solutions were prepared from budesonide (BD) and budesonide plus Rhodamine B (RH) feed solutions at 5% w/w (5 mg BD or BD+RH per 100 mg of total solids). In both cases, BD and RH were respectively added to the ethanolic and aqueous solutions while the lactose content was reduced by an equal (weight) amount, such as to maintain the total solid content of the final feed solution at 0.1% w/v. To limit the effect of evaporation on the total volume of the liquid media, the feed solutions were subjected to gentle stirring (5 min) at 50 ºC; the boiling points of H 2 O:EtOH at 30:70 v/v is at 85 ºC while that at 15:85 v/v is 80 ºC. 37 The feed solutions were spray dried using a Buchi Mini Spray Dryer B-191 (Buchi, Switzerland) operating at: inlet temperature, 100 ºC; airflow, 600 L/h; respective aspirator and pump rates of 100 % and 4.5 mL/min; and, outlet temperature of 60-65 ºC. To calculate the yield of the spray-drying process, each batch of MCs was weighed and 7 the percentage yield was determined from: Yield%=m f /m i ×100; where m i is the initial mass of solids in feed solutions and m f is the collected mass of MCs. To quantify drug loading, an accurately weighed amount of ca. 2 mg of each sample was added to EtOH (5 mL). This mixture was stirred continuously for 24 h before the solid content was separated by centrifugation (4000 rcf, 15 min). The drug content in the supernatant was determined by HPLC and percentage loading was calculated from: DrugLoad%=m BD /m BD-MC ×100, where m BD is the determined mass of budesonide and m BD-MC is the mass of drug loaded MCs dispersed in EtOH. In a similar manner, the drug loading of RH in the carriers was quantified spectrofluorimetrically following dissolution of the dye-containing carrier (3 mg) in EtOH (10 mL). Microparticles were stored in a CaCl 2 desiccator.
Scanning electron microscopy and ζ-potential studies. To assess particle morphology, both empty and loaded microparticles were visualized using a Zeiss SUPRA 35VP SEM microscope.
Dispersion stability studies were performed by means of a Zetasizer Nanoseries Nano-ZS analyzer (Malvern, UK). Microparticles were dispersed in distilled water (0.2 mg/mL), sonicated (15 s), and ζ-potential determinations were performed in triplicate.
Infrared spectroscopy and thermal analysis. The infrared spectra (650-4000 cm Laser diffraction analysis. Laser diffraction (Malvern Spraytec; Malvern, UK) studies allowed the evaluation of the particle size distribution (PSD) of loaded carriers: Gelatin capsules were filled with approximately 15 mg of the formulation under study, and these powders were 8 delivered by attaching a breath-activated spray delivery device to a USP throat that had been mounted onto the Spraytec device. A 300 mm focal length lens (specified for the particle size range 0.1-900 µm) was used and the respective refractive indices for particles and dispersant (air) were set at 1.330 ± 0.001 and 1.000 ± 0. In an effort to assess the capability of RH-loaded microparticles to penetrate the mucus layer of the respiratory system, preliminary permeation studies were conducted by means of an established in vitro model.
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(The adopted model is not capable of simulating the in vivo conditions; it is a tool for the pre-screening of the capability of carriers to participate in mucoadhesive interactions.) This barrier was simulated by a layer of gelatin that had been placed at the bottom of a test tube and covered with artificial mucus consisting of an aqueous dispersion of DNA, mucin, sterile egg yolk emulsion, diethylenetriaminepentacetic acid, sodium chloride, potassium chloride and RPMI medium. A specified volume of an aqueous dispersion of microparticles was placed on the artificial mucus layer. The test tubes were kept at room temperature for 24 h, after which time the amount of Rhodamine that had penetrated the mucus and became deposited on the gelatin layer was quantified by fluorimetry. Experiments were conducted in triplicate. by means of double-sided adhesive tape, an accurately weighted amount (ca. 5 mg) of the sample under test, while onto the holder stage of the device was deposited homogenised mucus (ca. 0.25 mL). The probe moved downward to establish contact with the mucus layer before being withdrawn at a specified constant rate. The experiments were performed under a force of 5 g, a contact time of 10 s and probe speed of 1 mm/sec. The mucoadhesion profiles were recorded as plots of force versus time.
In vitro release in Simulated Lung Fluid. Release studies were carried out in simulated lung fluid (SLF).
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Each BD loaded sample (8 mg) was separately suspended in SLF (4 mL) that had been maintained at 37 ºC. Dialysis bags (12,000 -14,000 molecular weight cut-off) were filled with each suspension (1 mL) and immediately immersed in an SLF-containing (20 mL) glass vial maintained at 37 ºC. Drug release was carried out over 24 h in a shaking thermostatic Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   12 was assessed by washing the cell cultures with DMEM (to remove the formulations), before fresh HBSS/HEPES buffer was added and the TEER being monitored for a further 240 min. 
RESULTS AND DISCUSSION
Evaluation of engineered microparticles. The solid composition of empty feed solutions, the calculated process yields and the ζ-potential values of empty MCs are presented at Table 1 .
Irrespective of variations in the proportion of excipients, in most cases, the spray drying process was associated with yields in the range 28 -32%. Indicative of the role of PVA as the core material of formulations, S1 was produced at a low yield. In light of literature reports, 43 it is assumed that the yield of the process.is markedly influenced by the proportion of DPPC in the S1
formulation (S1 has the highest content of DPPC among all formulations under consideration).
In the processing of samples with the same composition (S3-S7 and S5-S6), the proportion of Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 point of the more ethanolic medium does not accelerate the drying process, presumably due to molecular-level solvent association phenomena.
The surface charge studies reflected the strong dispersion stability of the empty particles in H 2 The influence of DPPC content on the ζ-potential was investigated in formulations having a fixed proportion of chitosan. Marked differences were noted between samples of low and high DPPC content. Indicative of plateau effects, however, S1 (40% DPPC) was characterized by a very similar ζ-potential to S5 (30% DPPC): respectively 29.3 ± 1.7 mV and 28.7 ± 1.5 mV. The corresponding differences between S2 (20% DPPC) and S3 (15% DPPC) were somewhat more pronounced at 40.8 ± 0.9 mV and 37.5 ± 0.6 mV, respectively. It is possible that the indicated increases in surface charge with increasing proportions of the nonionic core excipients, PVA and LCS, reflect the migration of the positively charged CS and DPPC molecules to the outer layer of particles. Amongst the empty MCs, the highest ζ-potential (51.4 mV) was associated with S4, which was formulated with triple the amount of CS (6% vs. 2%).
The size and morphological features of empty MCs were assessed by SEM imaging. Large particles (>>5 µm) were observed with S1 and S2 (Supplementary information, Figure S1 ). The SEM observations showed that other desiccated particles were approximately spherical and had smooth surfaces, and that their sizes were in the therapeutically useful range of 0.5-5.0 µm, Figure 1 (A, B, and C). The combined evaluations of experimental findings from the spray drying process, ζ-potential measurements and SEM imaging, allowed the selection of three candidate formulations for loading with BD and RH, namely: S3, S4 and S6. respectively for budesonide and Rhodamine-loaded microparticles. Similarly, SEM micrographs revealed that budesonide did not effect any significant changes to morphology, Figure 1 Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Particle size distribution and in vitro deposition. Particle sizes of loaded formulations, as determined by laser diffraction, are presented in Table 3 . The volumetric median diameter of the samples, which is related to the geometric diameter, was in the range 8.98-9.74 µm (P<0.05), while the percentage of particles with size <5µm was about 20% for BD1 and 23% for BD3;
representative size distribution plots are presented in Figure 4A -C. In accord with SEM data, BD3, which has the highest content of PVA and LCS, is confirmed as the formulation that exhibits the most useful, for the proposed use, size distribution profile. By contrast, the size distribution profile of BD1, which has the lowest PVA and LCS contents, was sensitive to increases in the volumetric percentiles and to the volumetric fine particle fraction. Data for BD2 The particle size analysis was complemented by in vitro deposition studies of Rhodamine-loaded formulations using the multistage-ACI. The Rhodamine formulations were prepared under identical condition to those used for the drug-loaded samples, such that they provide a fluorescently labelled congener of the therapeutically useful formulation, which can be used to compare size distribution data from laser diffraction experiments and the ACI-mediated aerosolization studies.
The deposition of the RH-loaded MCs onto the stages of the ACI is illustrated at Figure S2 (Supplementary Information). The deposited particles were seen to form as spots that were distributed over the surface of each level. This is attributed to capillary air flow at the lower Figure 4D and summarized in Table 3 .
Consistent with expectation on the basis of PVA-LCS content, ca. 65% of particles RH3
presented an aerodynamic diameter <5 µm and a mean diameter of ca. 4 µm. In accord with expectation, the low PVA and LCS-content formulations RH1 and RH2 were characterized by aerodynamic diameters of ca. 6 µm and respective FPFs of 23% and 38%. Since the PVA and LCS content of RH1 and RH2 is almost identical, the marked differences in behavior observed for these two formulations must be linked to the threefold difference in content of the aerolization excipient L-LC. The presence of large particles was reflected in the ACI size distribution profile of RH-loaded microparticles. The technique-dependent variability in observed mean particle size is well documented: laser diffraction measurements give appreciably longer mean diameters than impaction studies due to the effects on aerosolization performance of slip, shape and density.
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The density of microparticles studied by impaction appears to have been affected by the incorporation of RH. This is reflected by the lower MMAD values relative to the corresponding geometric diameters determined for BD formulations. It is possible that aerolization performance also reflects changes in the shape of microparticles, which in turn are consequent to the differences in composition. Marked differences between MMAD values and geometric diameters were observed with all three formulations.
The behavior of microparticles in artificial mucus. Dispersion in the mucin medium effected a reduction in the surface charge of empty formulations. The influence of the mucoadhesive content CS to the ζ-potential of the system is illustrated in Figure 5A . Indicative of the strong association of particles with mucin, the surface charge of S3 was seen to be reduced from 37.5 mV to 8.8 mV while those for S6 and S4 were correspondingly reduced to 9.8 mV and at 10. Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   18 mV. For comparison, the mucin medium is characterized by a surface charge of -18.6±1.45 mV.
Consistent with the strong association of mucin with MCs is the observed unimodal distribution profiles characterizing the ζ-potential measurements (Supplementary Information Figure S3 ).
In accord with their limited impact on the integrity of the mucus layer, the fluorescently modified formulations penetrated the artificial mucus layer to a limited extent, Figure 5B , with RH1 and RH3 presenting values of 3.25% and 2.21% penetration, respectively; these differences are statistically significant at the p<0.05 level. Notably, of these two formulations, it is RH1 (the formulation with the higher DPPC content; DPPC is a natural component of mucus) that displays a higher propensity for the mucin network. The influence of CS is exemplified by the behavior of RH2, which was characterized by a corresponding value of 5.34% (p<0.05).
Penetration through mucus was followed visually over a 24 h period ( Figure 5C ). Large amounts of RH1 and RH2 were seen to penetrate the artificial mucus layer and deposit onto the gelatin surface. For the RH3 formulation, the number of particles approaching the gelatin surface was seen to be limited by the observed rate of penetration through mucus.
The behavior of BD microparticles in homogenised mucus. The mucoadhesion performance of budesonide-loaded MCs was studied further with the aid of a texture analyzer. In an experiment designed to assess the mucoadhesive behavior of BD formulations, a physiologically relevant amount of each of BD1, BD2 and BD3 was mixed with a specified amount of homogenized mucus. A specified amount of each mixture (0.25 mL) was placed onto a glass slide with the aid of an automatic pipette. Each glass slide was placed on the TA stand. The TA probe was set to exert a force of 5g and lowered into the probed sample. After 10 seconds the probe was raised and the detachment profile was recorded. For control experiments, homogenised mucus was replaced by distilled water. A comparative assessment of the profiles Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 19 characterizing each of the BD formulations showed that all formulations were similarly mucoadhesive and also identified BD2 as that associated with slightly stronger mucoadhesive interactions (as quantified by the area under the mucoadhesion curve; work of adhesion) and also the desirable property of instantaneous (<<2 sec) onset of mucoadhesive behavior ( Supplementary Information, Figure S4 ).
To assess the effect of contact time between the BD solids and mucus, a sample of each type of microparticle was placed onto one side of double-sided adhesive tape, the other side of which was attached to the flat end of the probe ( Supplementary Information, Figure S5 ), and the probe (set at a force of 5g) was again lowered into the homogenised mucus (0.25mL) and allowed to interact for a specified time (10 sec) such that the microparticles become integrated into the test medium) before the raising of the probe; microparticles-free homogenised mucus provided the control. Data for the 10 sec experiment, presented as Supplementary Information (Figure S6 ), confirm the rapid integration of BD2 into the mucus layer. In accord with expectation on the basis of differences in surface energy, comparative data collected for the BD formulations in contact with homogenized mucus or with a distilled water control indicated the higher affinity of the formulations for mucus than for water, as is illustrated by the longer acting force of adhesion for BD2 against homogenized mucus as compared with that against distilled water. Comparison Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 21 at 4 h and 90% at 6h. These statistically significant (P<0.05) differences are attributed to the relatively high content of the water soluble molecules PVA and LCS in the BD3 formulation, as compared with the BD1 and BD2 homologues. Symptomatic of the influence exerted by its high proportions of lipid content and low proportions of water soluble components, BD1 released its entire drug content at a rate that decelerated progressively over the 24 h monitoring time period of the experiment.
Cell viability studies. The data presented in Figure 8 (A, B & C) indicate that, over the 48 h timespan and at the <2 mg/mL concentration level, budesonide-loaded microparticles do not exert any noticeable adverse effect on the cellular proliferation of Calu-3 cultures. In parallel, no permanent effect on the integrity of the Calu-3 cells membrane was observed upon treatment with the microparticles under the same experimental conditions ( Figure 8D ).
CONCLUSIONS
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FIGURE 6
BD2 on double-sided tape, tested against the water control. BD2 on double-sided tape, tested against homogenized mucus. Langmuir   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
